Mesoblast Limited (MESO,MSB.AX) reported that its loss attributable to the owners of the company for fiscal year ended June 30, 2025 widened to US102.14 million from last year's US$87.96 million. But net loss per share narrowed to 8.46 US cents from 8.91 US cents in the prior year.
Annual total revenues from cell therapy products were US$17.2 million, up 191% on prior year. Revenue growth driven by successful launch of Ryoncil in the final quarter.
MESO closed Thursday's regular trading at $15.95 down $0.17 or 1.05%. In the after-hours trading the stock further dropped $1.75 or 10.97%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.